🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  2. ATM-AVI

    Pfizer

    Serious Bacterial Infection

    phase 3 other terminated

    1 trial

  3. ATM-AVI

    Pfizer

    Complicated Intra-abdominal Infection

    phase 3 small molecule completed

    1 trial

  4. ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, Placebo to KJX839 (Inclisiran), ATORVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN

    Novartis Pharmaceuticals

    Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]) of recent onset.

    phase 3 small molecule active

    1 trial

  5. ATV

    Bristol-Myers Squibb

    HIV Infections

    phase 3 small molecule completed

    1 trial

  6. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  7. AZD0120, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, DARZALEX 1800 mg solution for injection, Dexamethason 1,5 mg JENAPHARM®, Kyprolis 10 mg powder for solution for infusion, Dexamethason 0,5 mg JENAPHARM®, Pomalidomide Zentiva 3 mg hard capsules, Pomalidomide Zentiva 2 mg hard capsules, Dexamethason 4 mg JENAPHARM, Kyprolis 30 mg powder for solution for infusion, Pomalidomide Zentiva 1 mg hard capsules, Pomalidomide Zentiva 4 mg hard capsules, Kyprolis 60 mg powder for solution f

    AstraZeneca AB

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  8. Abiraterone - Usual

    Lxo Ireland Designated Activity Company

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  9. AchilleS tendinoPathy treated with cortIcosteRoid injEctions.

    Disc Medicine

    Achilles tendinopathy

    phase 3 other active

    1 trial

  10. Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)

    AstraZeneca

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    1 trial

  11. Actilyse, polvo y disolvente para solución inyectable y para perfusión, Actilyse, polvo y disolvente para solución inyectable y para perfusión

    The George Institute

    People with acute ischemic stroke (AIS) due to large vessel occlusion of the anterior circulation.

    phase 3 small molecule active

    1 trial

  12. Active

    Aclaris Therapeutics

    Common Wart

    phase 3 small molecule completed

    1 trial

  13. Active CTC Assessment

    United Therapeutics Europe Ltd

    Adenocarcinoma of the Prostate

    phase 3 other terminated

    1 trial

  14. Active Surveillance

    Blackmores Limited

    Muscle-Invasive Bladder Carcinoma

    phase 3 other active

    1 trial

  15. Active referral

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 3 other active

    1 trial

  16. Acyclovir

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  17. Adsorbed COVID-19 (inactivated) Vaccine

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab completed

    1 trial

  18. Adtralza 150 mg solution for injection in pre-filled syringe, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

    LEO Pharma A/S

    Treatment of moderate-to-severe Atopic dermatitis

    phase 3 small molecule active

    1 trial

  19. Aficamten, Tablet placebo for aficamten 5mg tablet

    Cytokinetics (Ireland) Limited

    SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

    phase 3 small molecule active

    1 trial

  20. Afimkibart

    Hoffmann-La Roche

    Moderately to Severely Active Crohns Disease

    phase 3 small molecule active

    1 trial

  21. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Australia Pty Ltd

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  22. Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  23. Albuterol Spiromax

    Teva Pharma GmbH

    Exercise-Induced Bronchoconstriction (EIB)

    phase 3 small molecule completed

    1 trial

  24. Albuterol sulfate (ABS)

    Teva Pharma GmbH

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources